To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

June 10, 2019___

Today's Rundown

Featured Story

Merck inks $773M Tilos takeout to bag TGFβ cancer programs

Merck has struck a $773 million detail to buy Tilos Therapeutics. The takeover will give Merck control of a pipeline of cancer, fibrosis and autoimmune programs targeting the latent TGFβ complex.

Top Stories

Amid BMS R&D shuffle, F-star nabs its immuno-oncology executive

Last week, Bristol-Myers Squibb announced it was changing up its R&D structure and personnel as it subsumes new buy Celgene, and one of its key executives has now jumped ship to a small British biotech.

Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist

Eli Lilly is planning to test its closely watched diabetes drug tirzepatide in a phase 2b nonalcoholic steatohepatitis (NASH) trial. The expansion is driven by midphase Type 2 diabetes data suggesting the dual GIP and GLP-1 receptor agonist improves markers associated with NASH.

[Sponsored] Advancing a Diabetes Multi-Registration Program

Read the case study to learn how Covance helped a sponsor who wanted to get all sites for a 2,700 patient study up and running as quickly as possible. Covance leveraged their proprietary historical investigator performance database to see which investigators outperformed their peers on a consistent basis and had the capacity to run multiple studies at the same time.

Janssen inks nference AI research pact

Looking to broaden its use of artificial intelligence to help lock down its R&D work, Johnson & Johnson’s biotech unit Janssen has penned a new deal with AI specialist nference.

ADA: NGM backs up case for once-monthly dosing of Merck-partnered NASH drug

At the American Diabetes Association meeting, NGM Biopharmaceuticals presented new data from a phase 1b trial to back up what it and partner Merck hope will be a selling point for their experimental drug to treat nonalcoholic steatohepatitis in patients with or without diabetes: a convenient dosing schedule.

Special Report—The top 20 highest-paid biopharma CEOs of 2018

As spring rolls on each year, proxy filings pile up, disclosing executive pay for the prior year. And as in past years, FiercePharma has tracked the info to present the top CEO pay packages in biopharma, ranging from nearly $60 million in 2018 down to $16 million.

Resources

[Whitepaper] Agile Competitive Intelligence Strategies For Healthcare

What is agile competitive intelligence, and how can it help take market research to the next level?

[POCKET GUIDE] Reference and Literature Management Made Easy

Get 5 quick tips for faster research and better results!

[Report] Precision medicine from concept to clinic

In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report.

[Whitepaper] Flow Chemistry: A Scale-Up Solution for Modern API Development & Manufacturing

Increase Safety & Flexibility with Flow Chemistry

[On-Demand Webinar] Lessons Learned Implementing an End-to-End RIM Solution

IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now.

[Whitepaper] Site-specific, Patient-centered and Whip-smart: Enrollment Assistants Adapt to a Shifting Landscape

Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients.

[Case Study] Clinical Supply Management

Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

[Video] Demand Led Services and Clinical Supply Efficiency

Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels.

[eBook] Strategies for Efficient Clinical Supply Management and Forecasting

Download the eBook to explore a proactive approach for clinical supply management.

[Whitepaper] Choosing the Best Sterile Dosage Form for Phase I Clinical Supply Needs

Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs.

[Whitepaper] Delivering oral solid dose product to Phase I Clinic in 14 weeks

Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks.

[Paid Marketplace] Accelerating DoD’s Fielding of Prototypes for Medical Countermeasures

MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter.

Events